FOR IMMEDIATE RELEASE
FOR ADDITIONAL INFORMATION, CALL
Marita Gomez, 630-936-9105
maritag@crispsolution.net
Duska Anastasijevic, Mayo Clinic Public Affairs
newsbureau@mayo.edu
St. Louis, Mo., March 17, 2020 — DYNALABS and Mayo Clinic have joined forces to launch ANiGENT, a new company whose proprietary software uses machine learning to deliver a state-of-the-art drug diversion surveillance system. The novel platform will help hospitals and health systems reduce patient and worker harm from potential drug diversion and prevent regulatory or legal risk. The collaboration unites the clinical expertise of Mayo Clinic with analytic lab testing company DYNALABS, which offers an industry-leading technology.
Headquartered in St. Louis, Mo., the new company will be led by V.C. Jun Fabella Jr., chief executive officer and managing partner, and Charles D’Amato, chief product officer and managing partner. Previously, Fabella was president of DYNALABS and D’Amato served as pharmacist and supervisor of the drug diversion prevention program for Mayo Clinic Hospital in Phoenix, Ariz.
“Healthcare organizations face mounting pressures to keep patients safe while looking for ways to reduce costs,” said Fabella. “They can lose millions from drug diversion annually, and they face serious regulatory fines for not having adequate controls to prevent these occurrences.”
“There is a rising demand to improve protocols for preventing drug diversion,” added D’Amato. “Organizations are seeking out new technology that can solve these problems, and until recently, there was no such solution.”
“The active, predictive analytic system is an effective tool for continuous quality improvement that allows health systems to identify potential problems indicative of drug diversion and distinguish between wrong doing and human error,” said Mark H. Siska, RPh, chief pharmacy informatics officer at Mayo Clinic.
ANiGENT will deliver a comprehensive software solution that enables healthcare organizations to track and monitor all users and drugs at any location to prevent occurrences of drug diversion. The patent-pending software is based on the Medication Administration & Analysis Program (MAAP), a solution that Mayo Clinic has used at its own facilities. MAAP will leverage machine-learning algorithms to:
- Continually capture and analyze data
- Rapidly identify and prevent drug diversion
- Pinpoint areas that need process improvement
An additional value MAAP offers is its ability to recapture lost revenues by improving the charge capture process.
“While MAAP was initially designed to reduce a health facility’s risk of drug diversion, the software platform also corrected procedural gaps, lowering costs and improving revenue streams,” said Fabella.
ANiGENT’s first customer will be Mayo Clinic as the health system continues to integrate MAAP across its facilities.
ABOUT ANiGENT
ANiGENT is the first and only software provider to deliver a comprehensive solution that helps facilities track and monitor all users and all drugs in all locations. The company is a collaboration between Mayo Clinic and DYNALABS, one of the premier analytical lab testing companies in the Midwest. ANiGENT delivers a comprehensive, patentpending solution based on Medication Administration & Analysis Program (MAAP). ANiGENT’s MAAP solution utilizes machine learning algorithm to identify and prevent drug diversion from occurring; pinpoint the areas that need process improvement; capture revenues lost; and, most importantly, protects patients and improve safety. For more information, visit: http://www.anigent.com/
